Highlights
IIA supported (ever)Profile claimed by owner
About
Redefining Inhalation Therapy
FiBreath was created to address the global burden of respiratory disease. The company’s vision is to empower over 100 million asthma and COPD patients to breathe more easily and reclaim active lives. Operating in stealth mode, FiBreath is developing a novel inhaled‑therapy platform designed for deep‑lung delivery and enhanced patient outcomes. The business model focuses on licensing its platform to leading pharmaceutical and inhaler manufacturers in exchange for royalties.
Identity
| Name | FiBreath |
|---|---|
| Slug | fibreath |
| Type / kind | startup |
| Source _id | ZkoZSq01ETQ3iSREDn2Z85uYlCLw9Y0JvcJqrIV2mJebRqpw4CZctY |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | North District |
| HQ city | Haifa |
| HQ address | Haifa, Israel |
Web & social
| Website | https://fibreath.com |
|---|---|
| https://www.linkedin.com/company/107954894 |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrug Delivery
Target customers
Healthcare & Life SciencesHealthcareProvidersInsurance CompaniesLife SciencesPharmaceuticalsBiotechnologyMedical Devices IndustryMedical Products
Business models
B2B
Tags
inhalationasthmarespiratorystealthmodedrug-delivery
Funding
| Total raised | $9K |
|---|---|
| Current stage | Pre-Funding |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}